ABSTRACT
BACKGROUND: Data from numerous studies demonstrate the high frequency of vitamin D deficiency (VDD) and insufficiency (VDI) in many countries worldwide that depend on age and sex, seasons, country, and concomitant pathology. This research aimed to study vitamin D status in the Ukrainian population during 2016-2022 years depending on age, sex, month, and year of the observation, and compare the results with the data of previous Ukrainian epidemiologic studies. METHODS: In a single-center cohort study, we analyzed the serum total 25-hydroxyvitamin D (25(OH)D) level in 7,418 subjects aged 20-99 years. The analysis was performed depending on age, sex, month, season, and year of the observation. Also, we compared the results with the data of previous Ukrainian studies. 25(OH)D level was measured using the electrochemiluminescence method. RESULTS: The mean serum 25(OH)D level in the total group was 31.0 [22.3-41.1] ng/mL, the lowest level was in the age group 90-99 years old. No gender differences were found in 25(OH)D levels, except the one for the women aged 60-69 years old who had higher vitamin D levels compared to male parameters. 41.6% of the subjects had an optimal (> 30-50 ng/mL) 25(OH)D level, 27.3% had VDI, and 19.5% had a VDD. The suboptimal and high serum concentration of 25(OH)D (> 50-100 ng/mL) was found in 11.4% of the subjects. Also, we established the increase of serum 25(OH)D level from 2016 to 2022 with the highest values in 2020-2022. Seasonal variations of 25(OH)D concentration confirmed the highest index in autumn (33.0 [24.0-42.4] ng/mL) and the lowest one in the spring (28.5 [19.7-38.7] ng/mL) with the highest 25(OH)D level in September and the lowest one in March. CONCLUSION: Our results confirmed a decrease in VDD and VDI in 2020-2022 in the Ukrainian population compared to the previous years (2016-2019) and previous Ukrainian studies with similar age and seasonal particularities. It may be the consequence of an improvement in public awareness of global vitamin D deficiency, its positive skeletal and extra-skeletal effects, as well as more intensive vitamin D supplementation due to the COVID-19 pandemic in the recent years.
ABSTRACT
Data from previous studies demonstrate the high frequency of deficiency and insufficiency of vitamin D in Ukraine, as in the world, which varies depending on the age and gender of the population, the season, the region of residence, and the type of concomitant pathology. The purpose of the study was to assess the vitamin D status in the Ukraine population during 2016-2022 years depending on age, sex, month, and year of observation. In a single-center cohort study, serum 25-hydroxyvitamin D (25(OH)D) level was analyzed in 7105 subjects aged 20-99 years. The analysis was performed depending on age, sex, month, and year of observation. The mean serum 25(OH)D level in the total group was 30.9 [22.1-41.0] ng/ml, the lowest level was in the age group 90-99 years old and the highest one was in the subjects aged 40-69 years old. 52.7% of the subjects had a sufficient vitamin D level, 27.4% had insufficiency, and 19.9% had a deficiency of vitamin D. No gender differences were found in the serum level of 25(OH)D, except the one for the women aged 60-69 years old, who had higher vitamin D levels compared to males parameters. Seasonal 25(OH)D levels variations indicated the highest values in September and October and the lowest ones in February and March. Additionally, we established the increase of serum 25(OH)D from 2016 to 2021 with the highest values in 2020 and 2021. Our data confirmed a decrease in vitamin D deficiency and insufficiency in 2021 and 2022 in the Ukrainian population compared to previous years (2016-2019) and previous studies in the Ukrainian population while maintaining their age-related and seasonal characteristics. It may be associated with an improvement in public awareness of global vitamin D deficiency and its positive skeletal and extraskeletal effects, as well as the COVID-19 pandemic in recent years. © N. V. Grygorieva, A. S. Musiienko, M. A. Bystrytska, T. Yu. Solonenko.
ABSTRACT
Background: Nowadays, the COVID-19 and its complications are considered an important medical issue with aggravated medico-social outcomes, both at the worldwide scale, and in terms of various individual countries. Despite the recent ASBMR, AACE, Endocrine Society, ECTS and NOF recommendations according to osteoporosis management in the era of COVID-19 the influence of antios-teoporotic drugs on disease incidence and severity continue to be studied [1, 2]. Objectives: The purpose of this study was to assess the COVID-19 risk for the patients receiving the parenteral bisphosphonate or Denosumab treatment, and the severity of its course in the systemic osteoporosis patients. Methods: We performed the phone survey and studied the results of 195 patients (92 % women;mean age-62.7±10.8 years, height-161.0±8.0 cm, body weight-68.9±12.3 kg) with systemic osteoporosis depending on the current use of parenteral antiresorptive drugs (Zoledronic acid, Ibandronic acid, or Denosumab, n=125) and compared the results with patients with osteoporosis who did not use any antiosteoporotic drugs previously (n=70). The mean duration of antiosteoporotic treatment did not vary across the groups, accounting for 15 [9-27] months. Prior to the beginning of the antiosteoporotic therapy, all the patients had a confrmed diagnosis of osteoporosis at the Ukrainian scientific-medical Center of osteoporosis. Results: We did not reveal any signifcant differences in the COVID-19 frequency and severity depending on the presence and type of parenteral antiosteoporotic therapy. Additionally, there were no differences depending on patients' age of sex, obesity presence, and other osteoporosis risk factors. The risk of COVID-19 in the patients with systemic osteoporosis did not differ depending on antiresorptive drug use, amounting (Odd Ratio (OR) 95 % CI) to 1.1 (0.6-2.0), or on the use of the defnite antiosteoporotic drug (for the Zoledronic acid-0.9 (0.4-2.0), the Ibandronic acid-1. 1 (0.5-2.3), and for the Denosumab-1. 6 (0.5-5.2). Conclusion: Our study did not reveal any signifcant differences in the COVID-19 frequency and severity depending on the presence and type of parenteral antiosteoporotic therapy. We conclude that parenteral antiosteoporotic drugs (Zoledronic acid, Ibandronic acid, or Denosumab) do not have an influence on COVID-19 frequency and severity and can be recommended for the continuation of treatment of patients with osteoporosis.